Lu Kang Pharmaceutical: The approval notice for the marketing application of Lenvatinib Mesylate as a chemical raw material drug has been granted.

Lu Kang Pharmaceutical announced that the company recently received the "Approval Notification for the Market Launch Application of Lenvatinib Mesylate" issued by the National Medical Products Administration. The application for the drug's market launch has been approved. As of the announcement date, the company's cumulative investment in the research and development of this drug is approximately 5.73 million yuan.